Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMay 26, 2026
DataAggregated Company Financials
Companies20
  • 7D1.5%
  • 3M12.8%
  • 1Y-31.7%
  • YTD-12.4%

Over the last 7 days, the Healthcare industry has risen 1.5%, driven by gains from Novo Nordisk of 1.0%. In contrast, the industry has lost 32% in the last 12 months. Earnings are forecast to grow by 2.5% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 26 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.4x11.6x3.6x
Thu, 23 Apr 2026DKK 1.5tDKK 447.3bDKK 129.9b19x11.7x3.4x
Sat, 21 Mar 2026DKK 1.5tDKK 447.7bDKK 130.0b16.2x11.2x3.2x
Mon, 16 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b15.7x13.5x4.1x
Wed, 14 Jan 2026DKK 2.2tDKK 454.0bDKK 137.0b18.6x16.2x4.9x
Fri, 12 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b17.4x14.1x4.2x
Sun, 09 Nov 2025DKK 1.8tDKK 453.0bDKK 135.7b17.6x13.1x3.9x
Tue, 07 Oct 2025DKK 2.2tDKK 447.4bDKK 141.7b18.4x15.8x5x
Thu, 04 Sep 2025DKK 2.1tDKK 447.5bDKK 141.8b24.2x14.9x4.7x
Sat, 02 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.3x14.6x4.3x
Mon, 30 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Wed, 28 May 2025DKK 2.5tDKK 423.9bDKK 124.7b25.8x20.3x6x
Fri, 25 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.9x18.8x5.6x
Sun, 23 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.7x23.4x6.9x
Tue, 18 Feb 2025DKK 3.1tDKK 409.9bDKK 121.5b26.7x25.3x7.5x
Thu, 16 Jan 2025DKK 3.2tDKK 387.5bDKK 111.3b28.8x29x8.3x
Sat, 14 Dec 2024DKK 3.9tDKK 387.4bDKK 111.3b30.5x34.9x10x
Mon, 11 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Wed, 09 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.4x38.4x11x
Fri, 06 Sep 2024DKK 4.5tDKK 371.9bDKK 107.2b35x42.3x12.2x
Sun, 04 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b36.6x42x12.6x
Tue, 02 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b34.2x47.4x14.2x
Thu, 30 May 2024DKK 4.6tDKK 355.3bDKK 106.2b36.5x43.3x13x
Sat, 27 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b33.1x45.3x13.2x
Mon, 25 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Wed, 21 Feb 2024DKK 4.3tDKK 340.1bDKK 98.9b38x43.9x12.8x
Fri, 19 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.8x42.1x11.8x
Sun, 17 Dec 2023DKK 3.5tDKK 320.5bDKK 90.0b32.9x38.7x10.9x
Tue, 14 Nov 2023DKK 3.6tDKK 320.0bDKK 90.1b31.5x39.8x11.2x
Thu, 12 Oct 2023DKK 3.6tDKK 305.5bDKK 82.2b33.2x43.3x11.7x
Sat, 09 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b36.4x43.4x11.7x
Mon, 07 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Wed, 05 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b39.6x39.3x10.3x
Fri, 02 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.3x40.1x10.5x
Price to Earnings Ratio

40.1x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 30.2x.
  • The 3-year average PS ratio of 8.7x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.40%
Healthcare1.51%
Life Sciences3.66%
Medical Equipment2.73%
Biotech1.90%
Pharma1.30%
Healthtech0.66%
Healthcare Services0.35%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.2x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 289.001.0%
+DKK 13.3b		-37.2%PE10.5x
DEMANT DemantDKK 247.206.8%
+DKK 3.3b		-5.7%PE22x
ALK B ALK-AbellóDKK 263.005.1%
+DKK 2.8b		49.7%PE45.5x
GMAB GenmabDKK 1.72k2.0%
+DKK 2.0b		25.5%PE20x
HLUN B H. LundbeckDKK 41.824.2%
+DKK 1.7b		12.6%PE11.1x

Latest News

NOVO B
DKK 289.00
Novo Nordisk
7D
1.0%
1Y
-37.2%
DEMANT
DKK 247.20
Demant
7D
6.8%
1Y
-5.7%
HLUN B
DKK 41.82
H. Lundbeck
7D
4.2%
1Y
12.6%
Narrative Update • May 23

HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside

Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.
ZEAL
DKK 318.00
Zealand Pharma
7D
1.7%
1Y
-29.3%
Narrative Update • May 23

ZEAL: Obesity Trial Progress And Pipeline Execution Will Support Future Upside

Narrative Update: Zealand Pharma Zealand Pharma's updated analyst price target has moved lower from DKK 611 to DKK 519, as analysts factor in reduced fair value estimates and more cautious assumptions on long term revenue growth and future P/E following recent price target cuts and rating downgrades tied to the Phase II obesity data and a reassessment of petrelintide's competitive position. Analyst Commentary Recent research has shifted sharply more cautious after the Phase II obesity data for petrelintide, although there are some indications of renewed optimism in more recent commentary.
COLO B
DKK 403.60
Coloplast
7D
-0.2%
1Y
-36.7%
Analysis Article • May 20

Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...
EMBLA
DKK 26.95
Embla Medical hf
7D
3.3%
1Y
-20.7%
Narrative Update • May 19

EMBLA: Share Cancellations And Renewed Capital Authorisations Will Support Future Upside

Analysts have kept their DKK price target for Embla Medical hf. broadly steady at DKK 33.3, reflecting only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions in their updated models.
AMBU B
DKK 68.15
Ambu
7D
6.2%
1Y
-32.6%
Narrative Update • May 19

AMBU B: Lower P/E Expectations Will Support Future Upside Repricing

Analysts have trimmed their price target on Ambu from DKK 110.34 to DKK 88.80, reflecting a more cautious stance following a downgrade in recent research. The revised target still assumes steady revenue growth and a lower future P/E multiple.
GMAB
DKK 1,723.50
Genmab
7D
2.0%
1Y
25.5%
STENO
DKK 1.15
Stenocare
7D
-4.2%
1Y
172.6%
VIRO
DKK 10.90
ViroGates
7D
-2.7%
1Y
31.6%
ALK B
DKK 263.00
ALK-Abelló
7D
5.1%
1Y
49.7%
STRAP
DKK 590.00
Strategic Partners
7D
-4.8%
1Y
-45.4%